What Greywolf Therapeutics does

Greywolf Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Abingdon, UK, developing first-in-class oral small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) — a novel antigen modulation approach that targets Signal 1 of T-cell activation, the initial step of antigen recognition that has been therapeutically unexplored to date. By inhibiting ERAP1, the company alters the peptide repertoire presented on MHC-I molecules, creating novel immunogenic peptides in oncology (making tumor cells more visible to the immune system) and suppressing autoantigen presentation in autoimmune disease. The pipeline comprises two clinical-stage assets: GRWD5769, an oral ERAP1 inhibitor in Phase 1/2 development (EMITT-1 trial) in combination with cemiplimab across six solid tumor indications including NSCLC, urothelial carcinoma, HCC, MSS-CRC, SCCHN and cervical cancer, demonstrating objective response rates of 13-36% in patients with secondary anti-PD-1 resistance; and GRWD0715, a selective ERAP1 inhibitor in Phase 1/2 (EAST-1) for axial spondyloarthritis. The company also has discovery programs targeting ERAP2 and HLA molecules for additional oncology, autoimmunity and virology applications.

The company operates a pre-revenue, clinical-stage business model with no commercial products approved; future revenue is expected to flow from commercialization of its therapeutic candidates upon regulatory approval. The company funds operations through venture capital and grant financing, having raised approximately $99 million across Series B rounds (a $49M round in January 2023 led by Pfizer Ventures and Earlybird, and a $50M expansion in May 2024 led by ICG Life Sciences), plus a £1.1M Innovate UK grant and a £2.5M Series A2 for ERAP2 development in August 2025. Clinical trials are conducted across 28 centers in Australia, France, Spain and the UK, with the company maintaining a wholly-owned Australian subsidiary. Leadership includes co-founder and CEO Peter Joyce (former Vertex Pharmaceuticals R&D Lead) and recently appointed Chair Edwin Moses, the executive previously responsible for the $4.8 billion sale of Ablynx NV to Sanofi.

The company's go-to-market is structured around clinical development and eventual commercialization through standard pharmaceutical channels. Strategic marketing focuses on scientific communication at major conferences (ASCO, ESMO), press engagement, and building relationships with clinical investigators, pharmaceutical partners, and the investment community. The company has secured a clinical supply agreement with Regeneron for GRWD5769 combination studies and a strategic partnership with Genomics Ltd to leverage large-scale genetic datasets for autoimmune patient stratification.

Name

Greywolf Therapeutics

Legal name

Grey Wolf Therapeutics Limited

Website

https://greywolftherapeutics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Greywolf Therapeutics is a UK-based clinical-stage biotech developing first-in-class oral ERAP1 and ERAP2 inhibitors that modulate antigen presentation to treat solid tumors and autoimmune diseases, with two Phase 1/2 assets.

Ownership category

akta.pro rank

Product category

Immuno-oncology biopharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

Keywords

• Immuno-oncology therapeutics
• Antigen modulation technology
• ERAP1 inhibitors
• Clinical-stage biotechnology
• Autoimmune disease treatments

Headquarters

HQ city

Abingdon

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech company. Revenue expected from commercialization of novel antigen modulation therapies (GRWD5769 for oncology, GRWD0715 for autoimmunity) upon regulatory approval. The company is advancing through Phase 1/2 clinical trials with plans for Phase 2 and eventual market launch.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Greywolf Therapeutics is a clinical-stage biotech developing first-in-class oral small-molecule ERAP1 inhibitors that modulate antigen presentation on MHC-I molecules to control T-cell activation. Its lead clinical assets are GRWD5769 (oncology, for solid tumors in combination with anti-PD-1 therapy) and GRWD0715 (autoimmunity, for axial spondyloarthritis), supported by discovery programs targeting ERAP2 and HLA molecules.

Product overview

Greywolf Therapeutics is a clinical-stage biotech company developing novel antigen modulation treatments that control T cell activation by modulating antigen presentation. The company's portfolio consists of two clinical-stage ERAP1 inhibitors: GRWD5769 (first-in-class oral small molecule for solid tumors, currently in Phase 1/2) and GRWD0715 (selective oral small molecule for axial spondyloarthritis, in Phase 1/2). Both products work by inhibiting ERAP1 to alter the antigenic repertoire presented on cell surfaces, making tumors more visible to the immune system in oncology or preventing presentation of autoantigens in autoimmune diseases. The company also has discovery programs targeting ERAP2 and various HLA molecules (Classical HLA, Non-Classical HLA) for virology applications.

Differentiator

Problem solved

Functional benefit

Products and services

• GRWD5769 GRWD5769 is a first-in-class oral small-molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) for treating advanced or metastatic solid tumors. Administered as an oral capsule in combination with cemiplimab (anti-PD-1), it generates alternating antigenic repertoires to broaden T-cell responses and prevent T-cell exhaustion. It is in Phase 1/2 clinical development.
• GRWD0715 GRWD0715 is a first-in-class selective, potent oral small-molecule ERAP1 inhibitor designed to treat axial spondyloarthritis (axSpA) by interrupting autoantigen presentation and preventing damaging T-cell activation at the source of autoimmune disease. It is currently in Phase 1/2 clinical development.

Quantifiable outcome

• 13-36% Objective Response Rate (ORR) across six solid tumor cohorts in patients with secondary anti-PD-1 resistance
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Genomics LtdcoreStrategic or Co-development Partner · 29 April 2026Strategic partnership to study endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) and their role in autoimmune diseases. Genomics curates and analyzes large-scale genetic datasets to link ERAP enzyme variants with multiple autoimmune diseases, helping Greywolf identify patient populations for its autoimmune disease treatments including its Phase 1 program in axial spondyloarthritis.
• RegeneronminorImplementation/ SI/ Consulting PartnerSupply agreement for GRWD5769 clinical trial materials. Regeneron provides clinical trial supply of therapeutic agents for combination studies.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths5 records

Competitive moat4 records

Key risks6 records

Customer concentration

• LinkedInlinkedin.com/company/grey-wolf-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greywolf Therapeutics